Compare Fabrinet (FN) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Hinge Health Inc. Class A Common Stock — how do they compare? Fabrinet trades at $384 (market cap $15.33B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Fabrinet is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 31 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FN | HNGE | |
|---|---|---|
Market Cap | $15.33B | $8.48B |
Volume | 1,120,187 | 879,799 |
Sector | Technology | Health |
52-Week High | $746.47 | $105.14 |
52-Week Low | $374.91 | $31.17 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $14.46B | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $427.82, down 6.26% in the last session amid broader market volatility. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and robust 45% revenue growth in Q4 2026. Technical indicators present a mixed picture with a bullish overall signal but bearish moving averages, while support levels cluster around $407-$441. The company benefits from surging AI data center demand and capacity expansion initiatives.
Fabrinet's outlook remains positive driven by AI infrastructure growth, though risks include customer concentration and margin pressure. Analysts project 64% upside to the $769.50 consensus target with unanimous bullish sentiment (18 buys, 0 sells). The stock offers exposure to high-growth optical manufacturing but faces execution risks in capital expansion.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
